S100B protein expression in the heart of deceased individuals by overdose: a new forensic marker?

Faa, Armando; Senes, Giancarlo; Locci, Annalisa; Pampaloni, Pietro; Pais, Maria Elena; Piras, Bruno; d’Aloja, Ernesto

doi:10.6061/clinics/2012(07)19

Cited by 9 publications

(5 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Як доповнення до переліку важливих функцій кальційзв'язувального білка S-100b треба зазначити, що цей білок залучається також до регуляції формування серцево-судинної системи та вважається біохімічним маркером ушкодження цієї системи після шунтування та дилатаційної кардіоміопатії, після інфаркту міокарда (Faa et al, 2012), травм серця та головного мозку (Tsoporis et al, 2010). S-100b запропонований як маркер негативного прогнозу у пацієнтів із вадами серця для виявлення ризику розвитку гіпоксіє-ішемічної енцефалопатії (Faa et al, 2012).…”

Section: рис 3 концентрація рівня S-100b у гіпокампі мозочку та коunclassified

The role of astroglial proteins in the brains of rats under the influence of doxorubicin and Humilid

2016

View full text Add to dashboard Cite

Doxorubicin causes toxic side effects which result in profound changes in various organs including the heart muscle, which leads to the development of cardiomyopathy, with further complications, as our earlier studies have shown. But there are complications in treatment by anthracycline chemotherapy. The reduction of toxicity of cytotoxic drugs without reduction of their antitumor action remains an important medical challenge. The S-100b and glial fibrillar acid protein (GFAP) are the key astroglial proteins which are widely used as biomarkers for neurotraumas and strokes. Thus the purpose of our work was to study the GFAP and S-100b levels under the experimental model of doxorubicin-induced cardiomyopathy and the effect of the cytostatic separately or combined with Humilid. The level of studied proteins was measured by ELISA using monospecific antibodies against GFAP and S-100b (Sigma, USA), secondary anti-IgG labeled with horseradish peroxidase (Sigma, USA) and GFAP and S-100b standards (Sigma, USA). The experiment was conducted on white Wistar male rats weighing 210 ±50 g, which were divided into 3 groups with 8 animals in each: 1 – control, rats received saline i/p, 2 – doxorubicin 1 mg/kg i/p once weekly during 4 weeks, 3 – doxorubicin by the same scheme plus 0.01% solution of Humilid during 4 weeks. Under impact of doxorubicin an increase of fibrillar GFAP content in the rats’ hippocampus was shown, which may have occurred as a result of the proliferation of astrocytes. An increase of concentration of S-100b to 20–26% compared with the control animals was also detected in the hippocampus, thalamus and the cerebral cortex of the studied animals. Concomitant administration of doxorubicin with Humilid partially prevented the increase in concentration of GFAP and S-100b in the rats’ hippocampus. The reciprocal change in the level of S-100b and GFAP in the peripheral nervous system of the heart tissue was defined with a high degree of correlation under impact of doxorubicin. Accordingly, we have proposed the hypothesis that the increase in of the filament GFAP in the hippocampus may occur due to the development of the ischemic state under the impact of doxorubicin-induced cardiomyopathy. Humilid with doxorubicin prevented changes in the researched astroglial proteins of the heart muscle and brain parts of rats.

show abstract

Section: рис 3 концентрація рівня S-100b у гіпокампі мозочку та коunclassified

The role of astroglial proteins in the brains of rats under the influence of doxorubicin and Humilid

2016

View full text Add to dashboard Cite

show abstract

“…The other member of S100 family, S100B protein expression was suggested as a new forensic marker for cocaine-induced heart injury (19). The crucial role of S100A1 for cardiac performance and contractility was reported (20,21).…”

Section: Discussionmentioning

confidence: 99%

Protective Effect of Pycnogenol<sup>®</sup> on Cisplatin Induced-Cardiotoxicity in Rats

Eryılmaz¹,

Aksun²,

Demirci³

2018

meandros

View full text Add to dashboard Cite

Anah tar Ke li me ler Kardiyo-onkoloji, Pycnogenol Öz AbstractObjective: This study investigated the cardiotoxicity of cisplatin (CIS) on rat heart by using the oxidative damage of the rat myocardium, Troponin I and serum S100A1 levels. Previous studies have reported that cell-protective effect of Pycnogenol® (PYC) depended on its antioxidant and anti-inflammatory properties. Hence, the myocardial protective effect of PYC was investigated in this study. Materials and Methods: Rats were randomly assigned to four groups with 5 per group. The experimental groups were as follows: Control Group, Pycnogenol Group: 10 mg/kg Pycnogenol intraperitoneally for 7 days, Cisplatin Group: 15 mg/kg single injection of cisplatin on the 5 th day intraperitoneally, Cisplatin + Pycnogenol Group: 10 mg/kg Pycnogenol for 7 days intraperitoneally, plus 15 mg/kg single injection of cisplatin on the 5 th day. The heart and serum samples were obtained on the 8 th day. Results: CIS and PYC Co-treatment group had increased catalase level (from 43.61±15.16 to 60.80±21.36, p< 0.019) and prevented Troponin I elevation (from 7.34±6.20 to 3.03±1.36). The S100A1 level was significantly reduced by CIS (from 10.25 ±8.8 to 3.99 ± 2.87, p< 0.035) and was restored by PYC treatment (32.07±29.23). Conclusion: Injured cardiomyocytes released Troponin I after exposure to CIS and PYC, which can protect the cells from CIS cardiotoxicity,increased the tissue catalase level. Additionally, PYC treatment increased serum level of S100A1.Amaç: Bu çalışma sıçan kalbi üzerinde sisplatin (CIS) kardiyotoksisitesini, sıçan miyokardı oksidatif hasarını, Troponin I ve serum S100A1 düzeylerini kullanarak araştırmıştır. Önceki çalışmalar, Pycnogenol®'in (PYC) hücre koruyucu etkisinin antioksidan ve anti-inflamatuar özelliklerine bağlı olduğunu bildirmiştir. Bu nedenle, bu çalışmada PYC'nin miyokardiyal koruyucu etkisi araştırılmıştır. Gereç ve Yöntem: Sıçanlar randomize olarak grup başına 5 olacak şekilde dört gruba ayrıldı. Kontrol grupları, pycnogenol grubu: 10 mg/kg 7 gün boyunca intraperitoneal pycnogenol, 5 gün intraperitoneal olarak sisplatin'in 15 mg/kg tek doz enjeksiyonu, Cisplatin + Pycnogenol Grubu: 10 mg/kg Pycnogenol Intraperitoneal olarak 7 gün boyunca, artı beşinci günde 15 mg/kg tek sisplatin enjeksiyonu. Kalp ve serum örnekleri 8. günde elde edildi. Bulgular: CIS ve PYC eş-tedavi grubunda katalaz seviyesi artmış (43,61±15,16'dan 60,80±21,36'ya, p<0,019) ve Troponin I yükselmesini (7,34±6,20'den 3,03±1,36'ya)

show abstract

“…Another recent study shows that S100B protein accumulates in injured cardiomyocytes in drug-overdose sudden death cases, with protein immunoreactivity observed in the cytoplasm of cardiomyocytes. Therefore, S100B immunopositivity may be used as a new screening tool for the postmortem diagnosis of overdose-related cardiac death [160].…”

Section: S100bmentioning

confidence: 99%

Biomarkers Utility: At the Borderline between Cardiology and Neurology

Ion

Stafie

Mitu

et al. 2021

JCDD

View full text Add to dashboard Cite

Biomarkers are important diagnostic and prognostic tools as they provide results in a short time while still being an inexpensive, reproducible and accessible method. Their well-known benefits have placed them at the forefront of research in recent years, with new and innovative discoveries being implemented. Cardiovascular and neurological diseases often share common risk factors and pathological pathways which may play an important role in the use and interpretation of biomarkers’ values. Among the biomarkers used extensively in clinical practice in cardiology, hs-TroponinT, CK-MB and NTproBNP have been shown to be strongly influenced by multiple neurological conditions. Newer ones such as galectin-3, lysophosphatidylcholine, copeptin, sST2, S100B, myeloperoxidase and GDF-15 have been extensively studied in recent years as alternatives with an increased sensitivity for cardiovascular diseases, but also with significant results in the field of neurology. Thus, given their low specificity, the values interpretation must be correlated with the clinical judgment and other available investigations.

show abstract

S100B protein expression in the heart of deceased individuals by overdose: a new forensic marker?

Cited by 9 publications

References 52 publications

The role of astroglial proteins in the brains of rats under the influence of doxorubicin and Humilid

The role of astroglial proteins in the brains of rats under the influence of doxorubicin and Humilid

Protective Effect of Pycnogenol<sup>®</sup> on Cisplatin Induced-Cardiotoxicity in Rats

Biomarkers Utility: At the Borderline between Cardiology and Neurology

Contact Info

Product

Resources

About